We aimed to develop mouse CD38-specific nanobodies and hcAbs, to assess their binding epitopes, and to evaluate their capacity to induce cytotoxicity against tumor cells expressing CD38 in vitro as a basis for future in vivo studies of syngeneic MM models in immunocompetent mice. The gene discussed is CD38; the disease is Miyoshi myopathy.